Invox Pharma
Generated by Meeveem AI
"Respiratory drug device combinations delivered through proprietary soft mist inhaler technology"
Diepenbeek
•51 - 250 Employees
•Pharmaceuticals
About Invox Pharma
invoX develops complex respiratory drug device combination products using its proprietary Softhaler platform, a next generation soft mist inhaler. This propellant free technology delivers liquid formulations to the lungs, addressing asthma, COPD, pulmonary hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis through innovative and generic treatments. Through global partnerships, invoX brings medicines from development to commercial supply. The company operates an integrated supply chain covering device manufacture, sterile fill and finish, and packaging, supporting partners in delivering affordable respiratory treatments to patients worldwide.
65
Team Members
2016
Founded
Pharmaceuticals
Sector
Hybrid
Work Environment
Our Vision
Patients worldwide receive accessible, effective respiratory medicines that improve health and quality of life, addressing the global burden of chronic lung diseases and reducing barriers to treatment.
Our Mission
Harnessing next generation technology and development platforms, invoX develops and commercialises novel therapies to bring transformative medicines to patients through global partnerships.